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Abstract
Background: Point of care (POC) glucose meters are routinely used as a screening tool for
hypoglycemia in a neonatal setting. Glucose meters however, lack the same accuracy as laboratory
instruments for glucose measurement. In this study we investigated potential reasons for this
inaccuracy and established a cut off value for confirmatory testing.
Methods: In this prospective study, all patients in the neonatal intensive care unit who had a
plasma glucose test ordered were eligible to participate. Demographic information, sample
collection information (nine variables) and a recent hematocrit value were recorded for each
sample. Glucose measurements were taken at the bedside on the glucose meter (RN PCx) as well
as in the laboratory on both the glucose meter (LAB PCx) and the laboratory analyzer (PG). Data
were analyzed by simple and mixed-effects regression analysis and by analysis of a receiver operator
characteristics (ROC) curve.
Results: There were 475 samples analyzed from 132 patients. RN PCx values were higher than
PG values (mean = 4.9%), while LAB PCx results were lower (mean = -5.2%) than PG values. Only
31% of the difference between RN PCx – PG and 46% of the difference for LAB PCx – PG could
be accounted for by the variables tested. The largest proportion of variance between PCx and PG
measurements was explained by hematocrit (about 30%) with a greater effect seen at glucose
concentrations ≤4.0 mmol/L (≤72 mg/dL)(48% and 40% for RN PCx and LAB PCx, respectively).
The ROC analysis showed that for detection of all cases of hypoglycemia (PG < 2.6 mmol/L)(PG <
47 mg/dL) the PCx screening cut off value would need to be set at 3.8 mmol/L (68 mg/dL) requiring
20% of all samples to have confirmatory analysis by the laboratory method.
Conclusion:  The large difference between glucose results obtained by PCx glucose meter
compared to the laboratory analyzer can be explained in part by hematocrit and low glucose
concentration. These results emphasize that the glucose meter is useful only as a screening device
for neonatal hypoglycemia and that a screening cut off value must be established.
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Background
Adaptation to the extra-uterine environment requires the
newborn to establish glucose regulation and this transi-
tion usually takes place smoothly. However, some infants
such as those that are small or large for gestational age,
discordant twins, those with insulin dependent diabetic
mothers, or low or extremely low birth weight infants may
be at risk for neonatal hypoglycemia [1]. In these patients
glucose measurements are usually monitored at the bed-
side using point of care (POC) glucose meters. In addition
to requiring only a small amount of blood compared to
laboratory glucose testing, they provide immediate quan-
titative results allowing for more rapid intervention in
cases where low glucose values are found. However, meas-
urements using glucose meters are not as accurate as those
taken using laboratory methods and confirmation of low
levels are necessary for the diagnosis of neonatal hypogly-
cemia [2]. While the definition of clinically significant
neonatal hypoglycemia is itself controversial and may
vary depending on the clinical circumstance [3,4] main-
taining therapeutic plasma glucose levels at 2.6 mmol/L
or higher is considered desirable [3].
Glucose meters were originally designed for glucose self-
monitoring of patients with diabetes and concern has
been raised about their accuracy in the neonatal setting
[5]. In the neonatal intensive care unit (NICU) agreement
between the laboratory value and the bedside reading of ±
0.1 mmol/L or ± 5% at the hypoglycemic level is consid-
ered acceptable and should preclude the need for confirm-
atory or repeat testing [2]. Current POC instruments are
unable to achieve this agreement. The current recommen-
dations for analytical quality of glucose meters are those
targeted for diabetic patients. The American Diabetes
Association (ADA) recommends that glucose meters
should have a total error (bias and imprecision) of no
more than 10% for all concentrations [6]. More recently,
the International Organization for Standardization (ISO)
suggested that 95% of measurements should be within ±
0.83 mmol/L for glucose concentrations ≤ 4.2 mmol/L
and within ± 20% for concentrations > 4.2 mmol/L [7].
Few studies reporting the performance of glucose meters
in the NICU have been able to achieve any of the above
criteria or other reasonable accuracy criteria [8-10]. Both
pre-analytical (e.g., sample collection, physiologic fac-
tors), and analytical factors (e.g., precision) are known to
influence the performance of glucose meters but the
degree of contribution of individual variables to overall
measurement error is poorly understood. For this reason,
we undertook a study to assess both the sample character-
istics and the pre-analytical parameters that could influ-
ence the performance of glucose meter in a neonatal
population. At the same time we sought to determine an
optimal cut off value for our glucose meter to trigger con-
firmatory testing.
Methods
Subjects
Consecutive patients in the Neonatal Intensive Care Unit
(NICU) at the McMaster site of Hamilton Health Sciences
who had a plasma glucose test ordered were eligible for
inclusion in the study. A glucose meter reliability assess-
ment form was completed for each sample collected. It
included demographic information (patient identifica-
tion number, weight, and corrected gestational age), sam-
ple collection information (type of sample, glucose meter
identification number, registered nurse identification
number, if the first drop of sample was wiped away, if a
pipette was used to apply the sample to the glucose meter
strip, and if the sample was sent on ice), time data at dif-
ferent stages namely collection, transport, reception and
laboratory analysis, and results for the three glucose meas-
urements as well as the most recent hematocrit measure-
ment. The Hamilton Health Sciences/McMaster Faculty of
Health Sciences Research Ethics Board approved the
study. Parental consent was obtained for the additional
testing.
Glucose measurements
A minimum amount of capillary, arterial, or venous
blood was collected in a lithium heparin microtainer. A
portion was used for testing glucose at the bedside by a
registered nurse using the Precision PCx glucose meter
(RN PCx) (Abbott Laboratories, Medisense Products, Bed-
ford, MA) and the remaining sample was sent by a pneu-
matic tube system to the laboratory for testing by a
registered technologist on both the Precision PCx glucose
meter (LAB PCx) and the laboratory analyzer (PG) (Vitros
950, Ortho-Clinical Diagnostics, Rochester, NY). Eight
different glucose meters were used in the NICU and one
glucose meter was used in the laboratory. The same lot
number of test strips was used throughout the study. All
glucose meters and test strips used in this study were those
routinely used in the neonatal wards.
The Precision PCx glucose meter is a whole blood analyzer
that employs a disposable dry reagent strip containing an
electrode and glucose oxidase. Plasma from whole blood
diffuses through a porous membrane separating out the
erythrocytes. Glucose in the sample is oxidized to glu-
curonic acid and electrons from this reaction are trans-
ferred to the electrode surface through an electrochemical
mediator generating a current that is measured by the sys-
tem. The analytical coefficient of variation (CV) for the
PCx is 6.0% at 2.9 mmol/L and 5.0% at 15.9 mmol/L
using control solutions. The Vitros 950 method for
plasma glucose measurement also uses glucose oxidase
but with colorimetric detection. The analytical CV for the
Vitros analyzer is 2.7% at 5.3 mmol/L and 1.6% at 15.4
mmol/L using control solutions. The PCx glucose meter is
calibrated against the YSI 2300 analyzer whereas the Vit-BMC Pediatrics 2006, 6:28 http://www.biomedcentral.com/1471-2431/6/28
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ros 950 uses a calibrator for glucose traceable to the
National Institute of Standards and Technology (NIST)
Standard Reference Material (SRM) 917b. Glucose con-
centrations are given in SI units and can be converted to
conventional units by dividing by 0.055.
Hematocrit
Hematocrit was measured on the Beckman Coulter HMX
hematology analyzer (Beckman Instruments, Brea, CA).
Statistical analysis
The characteristics of the data were presented using the
sample size, median, range and percentages. Compari-
sons between glucose measurements (RN PCx and PG,
LAB PCx and PG, and RN PCx and LAB PCx) were done
using the Passing-Bablok regression method [11]. This
method makes no assumptions for sample distribution or
measurement errors. Pearson correlations were also calcu-
lated. A receiver operator characteristic (ROC) curve calcu-
lation was performed to establish a cut off value for
confirmatory testing. The Passing-Bablok regression, Pear-
son correlation and ROC curve calculations were done
using Microsoft Excel 2000 (Microsoft Corporation, Red-
mond, WA) with Analyze-it for Microsoft Excel (Analyze-
It Software, Ltd., Leeds, England).
Simple and mixed-effect regression analyses were per-
formed in SPSS 13.0 (SPSS Inc., Chicago, IL) to identify
variables that affect the agreements of these measure-
ments. Mixed-effect regression analysis was implemented
by using the mixed linear model procedure with restricted
maximum likelihood (REML) estimation method. This
procedure is robust and allows analyses to be performed
on data that exhibits correlation and non-constant varia-
bility due to repeated measures on the same patients. We
assumed an unstructured covariance matrix for all mixed-
effect analyses. First, we fitted a model with no covariate
to the data (null model). This model was made up of two
parts: a fixed part which contains the effect of the overall
intercept and a random part, which contains the random
effect for the intercept and the within patient residual. Sec-
ond, we fitted models with covariates to the data includ-
ing all the predictors as fixed variables and retaining the
same random component as in the null model. Model
selection and the test for the inclusion of random effects
were based on the statistical significance of a chi-squared
test for the change in -2 log likelihood between the mod-
els with and without the random effects. Third, we esti-
mated the intraclass correlation (ICC), which measures
the proportion of the total variance accounted for by
between patient variations. We used the approach of
Snijder and Bosker [12] to calculate the coefficient of
determination (R2) as the proportional reduction in the
estimated total residual variance from the null model to
the model with predictors. For all regression analyses, the
dependent variables were the difference between RN PCx
and PG, LAB PCx and PG, and RN PCx and LAB PCx. The
independent variables included capillary (1 = capillary, 0
= arterial, 0 = venous); arterial (0 = capillary, 1 = arterial,
0 = venous); pipette used to apply blood (1 = yes, 0 = no);
sample sent on ice (1 = yes, 0 = no) and group (1 = less
than or equal to 4.0 mmol/L, 0 = greater than 4.0 mmol/
L). Subgroup regression analyses (≤ 4.0 mmol/L and > 4.0
mmol/L) using hematocrit as the only independent varia-
ble was also carried out. A p-value less than .05 was con-
sidered to be statistically significant.
Results
Four hundred and seventy five samples taken from 132
patients were analyzed. The characteristics of the data col-
lected are shown in Table 1. Complete data for all glucose
measurements were available on 449 samples. Data miss-
ing in other categories ranged from 0.4 to 2.7% except for
the time between RN PCx and LAB PCx measurements
(5.7%).
The Passing-Bablok regression equations and correlations
for the blood glucose meter results compared to the labo-
ratory value were: LAB PCx = 1.08 PG – .58, r = .95; RN
PCx = 1.18 PG – .55, r = .91. The comparison between the
two PCx glucose measurements was RN PCx = .92 LAB
PCx – .58, r = .95. Despite these good correlations Figure
1 shows that 42% and 30% of glucose meter results, for
RN PCx and LAB PCx compared to PG results respectively,
were outside ± 15% total error limits. Furthermore, glu-
cose measurements done on the PCx were significantly
different from the PG measurements. The RN PCx results
were higher (mean = .20 mmol/L; 95% CI: .06; P < .0001;
SD = .81), whereas the LAB PCx results were lower (-.24
mmol/L; 95% CI: .07; P < .001; SD = .63) than the PG ref-
erence method. The mean differences were 4.9% and -
5.2% for the RN PCx – PG and LAB PCx – PG, respectively.
Further analysis of the data at low concentrations (≤ 4.0
mmol/L, n = 137) showed weaker associations: LAB PCx
= 1.19 PG – .74, r = .78; RN PCx = 1.43 PG – 1.11, r = .73.
The comparison between the two PCx glucose measure-
ments was RN PCx = 1.16 LAB PCx – .06, r = .83. The pro-
portion of RN PCx and LAB PCx results outside ± 15%
error limits were 38.7% and 5.1%, respectively.
RN PCx – PG
Only two variables showed significance in explaining the
difference between the RN PCx values and PG values after
adjusting for the effect of other variables (Table 2). Hema-
tocrit had the greatest effect (β = -4.871) on this differ-
ence, i.e., for an increase of .01 in hematocrit the
difference between RN PCx and PG values decreased by
approximately .05 mmol/L. Low glucose concentration
also explained some of the difference (β = .2619). OnBMC Pediatrics 2006, 6:28 http://www.biomedcentral.com/1471-2431/6/28
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average in the ≤ 4.0 mmol/L group the difference between
the RN PCx and the PG value was .27 mmol/L higher than
the >4.0 mmol/L group. Overall, the variables in this
study were able to explain about 31% of the difference
between RN PCx and PG glucose values.
LAB PCx – PG
The three significant variables that explained part of the
variation in the difference between the LAB PCx values
and the PG values after adjusting for the effect of other
variables were the capillary sample, group (≤ 4.0 mmol/L)
and hematocrit (Table 2). Hematocrit had the greatest
effect (β = -3.5710) on this difference, i.e., for an increase
of .01 in hematocrit the difference between LAB PCx and
PG values decreased by approximately .04 mmol/L. In the
≤ 4.0 mmol/L group the difference between the LAB PCx
and the PG value was on average .24 mmol/L (β = .2392)
higher compared to the > 4.0 mmol/L group. The average
difference between LAB PCx and PG values was .61 mmol/
L lower (β = .6092) if a capillary sample was used com-
pared to an arterial or venous sample. Overall, the varia-
bles in this study were able to explain about 46% of the
difference between LAB PCx and PG glucose values.
RN PCx – LAB PCx
The difference between the PCx values obtained at the
bedside and the PCx values obtained in the laboratory,
after adjusting for the effect of other variables, can be
explained in part by three variables, capillary sample (β =
.8918), pipette used to apply the sample (β = -.2478), and
hematocrit (β = -1.316)(Table 2). The average difference
between RN PCx and LAB PCx values was .89 mmol/L
higher than if a capillary sample was used compared to an
arterial or venous sample. If a pipette was used to apply
sample to the test strip at the bedside the difference
between the two measurements was on average .25
mmol/L lower than if no pipette was used. Hematocrit
had the greatest effect with an average difference between
RN PCx and LAB PCx values of approximately .01 mmol/
L per .01 unit increase in hematocrit. Overall, these varia-
bles and the other variables used in this study, explained
only 3% of the difference between RN PCx and LAB PCx
glucose values.
Effect of repeated measures on patients and difference in 
operators
Since samples were often collected more than once per
patient (1 to 23) the effect of repeated measures on the
Table 1: Characteristics of the data collected.
Characteristics N or median Range or percent
Patients (n) 132
Samples collected (n) 475
Samples per patient (n) 3 1 – 23
Weight (g) 1423 500 – 6609
Corrected Gestational age (weeks) 32 24 – 41
Hematocrit (volume fraction) 0.43 0.188 – 0.692
Glucose meter at the bedside (mmol/L) 4.7 1.4 – 17.5
Glucose meter in the laboratory (mmol/L) 4.2 1.1 – 17.5
Vitros Analyzer (mmol/L) 4.5 1.1 – 17.9
Sample Type (n)
Capillary 374 (78.7%)
Arterial 82 (17.3%)
Venous 12 (2.5%)
First drop of blood wiped away (n)
Yes 370 (98.9%)
No 2 (0.5%)
Pipette used to apply blood (n)
Yes 325 (68.4%)
No 142 (29.9%)
Sample sent on ice (n)
Yes 464 (97.8%)
No 8 (1.5%)
Time between RN PCx and LAB PCx 
measurement (min)
26 3 – 110
Glucose meters used at bedside (n) 8
Glucose meters used in lab (n) 1
Operators at the Bedside (n) 115
Median and range values are given for all variable data. Percentages are calculated using the number of samples collected.BMC Pediatrics 2006, 6:28 http://www.biomedcentral.com/1471-2431/6/28
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total variation was determined. The ICC values showed
the variation within patients accounted for only a minor
portion of the total variation in the differences between
measures (Table 2). The highest ICC was seen for RN PCx
– PG (ICC = .1185) with lower ICC values for LAB PCx –
PG (ICC = .0532) and RN PCx – LAB PCx (ICC = .0288).
There were 115 different nurses who performed the bed-
side glucose measurement. The ICC values were small for
all comparisons indicating minimal nurse specific effects
on the analysis [see Additional File 1].
Effect of hematocrit
Of all the variables in this study, hematocrit had the great-
est effect on the differences in glucose values between the
three measurements made. Figure 2 shows the negative
correlation between hematocrit and the difference
between the PCx and PG measurements. The data points
cross over the zero difference showing that glucose differ-
ences are positive if the hematocrit is lower and negative
when the hematocrit is higher. An additional mixed-effect
regression analysis was performed to see whether the level
of glucose concentration had an impact on the extent to
which hematocrit contributed to the difference between
measurements. This analysis showed that the R-square
was consistently higher in the ≤ 4 mmol/L group com-
pared to the > 4 mmol/L group (Table 3). Thus, hemat-
ocrit was a greater contributor to the difference between
measurements at lower glucose concentrations.
Comparison between PCx and PG measurements Figure 1
Comparison between PCx and PG measurements. Difference plots comparing glucose measurements on the PCx at 
the bedside (RN PCx) and in the laboratory (LAB PCx) with the corresponding glucose measurements on the laboratory ana-
lyser (PG). The two dashed lines represent the total error limits ± 15% .
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Hypoglycemia cut off value
There were 25 cases where the PG value was < 2.6 mmol/
L. However, only 13 of these cases had a bedside PCx
result < 2.6 mmol/L. The ROC curve in Figure 3 shows a
sensitivity of only 52.0% and a specificity of 97.9% at this
cut off for a positive predictive value (PPV) of 59.1%. The
cut off with the highest accuracy (sensitivity = 92%, specif-
icity = 91.7%) was 3.3 mmol/L. As the cut off value
increases the sensitivity of the PCx for detecting hypogly-
caemia increases. All hypoglycemic cases (PG < 2.6 mmol/
L) would be detected using an RN PCx cut off of 3.8
mmol/L at the expense of increasing the number of false
positive results from 9 to 88 (PPV = 22.1%). In practical
terms, for approximately every five samples with an RN
PCx value < 3.8 mmol/L sent for confirmatory testing one
sample would have a PG value < 2.6 mmol/L indicating
hypoglycemia.
Discussion
In this study glucose concentrations were found to be
higher when measured at the bedside (RN PCx) compared
to when the measurements were performed in the labora-
tory (LAB PCx or PG). The difference between glucose
meter results, either at the bedside or in the laboratory,
compared to the laboratory analyzer ranged from -29% to
39% and -32% to 21%, respectively. Only 58% of the all
RN PCx measurements and 39% at low values (≤ 4 mmol/
L) achieved a total error difference of 15% of the PG val-
ues. A 15% error limit is quite a liberal quality specifica-
tion that should be achievable and has been suggested
previously by the ADA and other groups [10]. A 15% error
on a value of 2.6 mmol/L is .4 mmol/L or a range between
2.2 to 3.0 mmol/L, which will significantly affect clinical
management. If the desired 5% error limit is applied the
range is reduced from 2.5 to 2.7 mmol/L. A rational error
estimate however depends on what can be achieved ana-
lytically (method variation) and biologically (variation
around a homeostatic set point). The concept of allowable
total error (TEa) combines analytical and biological varia-
tion. A frequently quoted TEa for glucose is 6.9% [13].
Therefore, for a hypoglycemic threshold value of 2.6
mmol/L the practical error around this value is closer to
2.4 to 2.8 mmol/L. The definition of neonatal hypoglyc-
emia must take into consideration the broad error limits
of glucose measurements, particularly when less accurate
glucose meters are used.
The poor accuracy of the PCx resulted in low sensitivity for
detecting hypoglycemia at the bedside. Approximately
half of the cases with laboratory glucose values less than
the operational threshold for hypoglycemia of < 2.6
mmol/L were missed using this threshold for the glucose
Table 2: Mixed-effects regression analyses.
RN PCx – PG LAB PCx – PG RN PCx – LAB PCx
Variables β Std. E P β Std. E P B Std. E P
Models with no covariate (null model)
Fixed Effects Intercept .1278 .0553 .023 -.2904 .0418 .000 .4210 .0382 .000
Random Effects Residual .4286 .0329 .000 .2670 .0200 .000 .5027 .0367 .000
Intercept .2190 .0474 .000 .1197 .0255 .000 .0282 .0195 .148
ICC .3382 .3095 .0531
Models with the effects of Covariates
Fixed Effects Intercept 1.7615 .5606 .002 1.552 .3135 .000 .3695 .5794 .524
Arterial sample .3230 .2303 .161 -.0450 .1584 .776 .3270 .2519 .195
Capillary sample .1648 .2209 .456 -.6092 .1469 .000 .8918 .2441 .000
Pipette used to apply blood -.0993 .0918 .280 - - - -.2478 .1003 .014
Sample sent on ice .3414 .2947 .247 - - - .2270 .3248 .485
Time between bedside and laboratory glucose measurement .0022 .0015 .134 .0013 .0010 .204 .0016 .0016 .330
Weight (divided by 100) .0047 .0061 .443 -.0039 .0040 .330 .0072 .0061 .239
Corrected gestational age -.0049 .0154 .751 .0065 .0100 .519 -0.122 .0156 .435
Hematocrit -4.871 .4283 .000 -3.5710 .2754 .000 -1.3164 .4338 .003
Group (≤ 4 mmol/L) .2619 .0744 .000 .2392 .0505 .000 .0271 .8034 .735
Random Effects Residual .3956 .0320 .000 .1974 .0151 .000 .5053 .0393 .000
Intercept .0532 .0239 .025 .0111 .0080 .167 .0150 .0189 .429
ICC .1185 .0532 .0288
R-Squared .3070 .4608 .0200
The analyses included fixed-effects and random-effects parameter estimates (β); approximate standard errors (Std. E) and p-values (P) for the 
difference between PCx and PG measurements taking into account all variables collected. RN, registered nurse (bedside glucose meter); LAB 
(laboratory glucose meter); and PG, plasma glucose (Vitros 950).BMC Pediatrics 2006, 6:28 http://www.biomedcentral.com/1471-2431/6/28
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meter. Recognizing that the highest sensitivity for detect-
ing hypoglycemia is necessary to avoid neurological
sequelae in both asymptomatic and symptomatic
neonates, the pertinent question is at what screening cut
off value should a blood sample be drawn and sent for
confirmatory testing? Increasing the screening threshold
value on the glucose meter increases the number of true
positive cases at the expense of including more false posi-
tive cases. To achieve 100% sensitivity for detecting
hypoglycemia, one in four of all samples screened in this
study would require confirmatory testing based on a
screening cut off value of 3.8 mmol/L. The poor accuracy
of glucose meters for detecting neonatal hypoglycemia is
well known and varies between glucose meters and study
populations [9,14]. Although this limitation attenuates
the advantage of bedside glucose monitoring with respect
to time, this method still reduces the number of larger
blood volume collections required for glucose testing in
the laboratory. The cut off value chosen for confirmatory
screening will be dependent on the glucose meter and the
comparator reference method. If NICUs have access to
POC blood gas analyzers with glucose modules (accuracy
is comparable to laboratory methods), the time delay for
confirmatory analysis would be reduced compared to
sending the sample to the laboratory for analysis.
Many variables have been shown to contribute to the inac-
curacy of glucose meters, but no study has incorporated as
many variables in a large mixed-effects analysis as this
present study. We found that only 31% of the variance
between the glucose meter at the bedside and laboratory
analyzer results could be attributed to the measured vari-
ables. Some of the unexplained variance may be due to
differences in calibration between the PCx glucose meter
Effect of hematocrit on PCx measurements Figure 2
Effect of hematocrit on PCx measurements. Effect of hematocrit on the difference in glucose measurements on the PCx 
glucose meter performed at the bedside (RN PCx) and in the laboratory (LAB PCx) compared to the laboratory analyzer (PG).
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and the Vitros analyzer. Surprisingly, and in contrast to
other studies, we found that neither time between bedside
and laboratory analysis, nor transport on ice were signifi-
cant variables in explaining the observed difference. The fall
in glucose concentration between bedside and laboratory
analysis suggests glycolysis had occurred, but this was not
supported by the time variable (not significant). The rate of
cord blood glycolysis 30 minutes post draw at room tem-
perature has been found to be about .33 mmol/L/h [15].
This is quite substantial, but in our study blood was kept on
ice and analyzed in less than one hour (mean = 35.2 min,
CI = 2.1 min). Although the activity of the neonatal red
blood cell glycolytic enzymes such as pyruvate kinase are
higher in neonate than in adult red blood cells [16],
enzyme kinetics are most likely to change from a rapid to a
reduced metabolizing state because of the sudden drop in
temperature and termination of glucose supply. No
detailed time studies have been done to examine the kinet-
ics of glycolysis immediately following blood withdrawal
and cooling on ice. Rapid glycolysis suggested by higher
bedside glucose value could have implications for the defi-
nition of an operational threshold and the management of
neonatal hypoglycemia.
Hematocrit was the largest and most consistent variable
accounting for the observed difference in glucose results in
all models compared. The manufacturer claims there is no
significant effect with hematocrits between .2 and .7. How-
ever, it is not clear from the product information material if
this range is also applicable for neonatal samples. All sam-
ples in this study had hematocrits essentially within this
range (.19 to .69). The hematocrit effect using filter-based
test strips is well known (including the PCx glucose meter),
although not all glucose meters have this problem [10].
Separation of plasma from cells for glucose measurement
occurs by membrane filtration in contrast to the conven-
ROC curve for neonatal hypoglycemia Figure 3
ROC curve for neonatal hypoglycemia. ROC curve for plasma 
glucose measured on the Vitros 950 (PG) and whole blood glucose 
measured at the bedside with the PCx glucose meter (RN PCx). The 
arrows indicate the PCx screening cut off values for hypoglycemia of 
2.6 mmol/L (suggested hypoglycemic screening threshold value for 
PG), 3.3 mmol/l (highest accuracy) and 3.8 mmol/L (highest sensitiv-
ity). The diagonal line indicates no discrimination.
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Table 3: Mixed effect regression with only hematocrit as the independent variable.
RN PCx – PG LAB PCx – PG RN PCx – LAB PCx
Variables ALL PG ≤ 4 
mmol/L
PG > 4 
mmol/L
ALL PG ≤ 4 
mmol/L
PG > 4 
mmol/L
ALL PG ≤ 4 
mmol/L
PG > 4 
mmol/L
Model with no covariate (null model)
Fixed 
Effects
Intercept .1278 (.023) .2664 (.000) .0743 (.292) -.2904 (.000) -.1427 (.003) -.3441 (.000) .4210 (.000) .4055 (.000) .4334 (.000)
Random 
Effects
Residual .4286 (.000) .1491 (.000) .5294 (.000) .2670 (.000) .1057 (.000) .3178 (.000) .5027 (.000) .1760 (.000) .6344 (.000)
Intercept .2190 (.000) .1748 (.000) .2638 (.000) .1197 (.000) .0910 (.000) .1498 (.000) .0282 (.148) .0563 (.061) .0274 (.349)
ICC .3382 .5397 .3326 .3095 .4626 .3204 .0531 .2424 .0414
Models with the effects of hematocrit
Fixed 
Effects
Intercept 2.1556 (.000) 2.1616 (.000) 2.2962 (.000) 1.3237 (.000) 1.1849 (.000) 1.5383 (.000) .9019 (.000) 1.0007 (.000) .8481 (.000)
Hematocrit -4.5545 (.000) -4.1764 (.000) -5.0828 (.000) -3.6237 (.000) -2.9218 (.000) -4.3113 (.000) -1.1054 (.005) -1.3189 (.006) -.9837 (.068)
Random 
Effects
Residual .4061 (.000) .1390 (.000) .5052 (.000) .2588 (.000) .1040 (.000) .3039 (.000) .4970 (.000) .1714 (.000) .6306 (.000)
Intercept .05437 (.013) .0287 (.204) .0621 (.063) .01226 (.176) .0145 (.262) .0089 (.461) .0265 (.172) .0499 (.081) .02625 (.383)
ICC .1181 .1711 .1095 .0452 .1224 .0285 .0506 .02255 .0400
R-Squared .2890 .4822 .2848 .2990 .3976 .3311 .0139 .0474 .0075
The analyses included fixed-effects and random-effects parameter estimates (p-values) for the difference between PCx and PG measurements for 
according to all, low (≤ 4 mmol/L) and high (> 4 mmol/L) glucose concentration. RN, registered nurse (bedside glucose meter); LAB (laboratory 
glucose meter); and PG, plasma glucose (Vitros 950).BMC Pediatrics 2006, 6:28 http://www.biomedcentral.com/1471-2431/6/28
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tional method of centrifugation. The rate of filtration and
the volume filtered depends on the properties of the sam-
ple. If the volume of plasma filtered varies then the glucose
concentration will vary since it is a function of the number
of molecules per volume. A sample with more red blood
cells will yield less plasma water then a sample with fewer
red blood cells because of the fixed analysis time between
sample application and result readout. The hematocrit
effect was greater in samples containing lower (≤ 4.0 mmol/
L) than in higher (> 4.0 mmol/L) glucose concentrations
since proportionally a change in volume will have a more
pronounced effect at low concentrations.
In essence, any variable that affects the flow of plasma
through the filter membrane will alter the glucose concen-
tration. These rheological factors may include the size and
shape of neonatal red blood cells, microclot formation in
samples, contamination by interstitial fluid, hemolysis,
altered protein quantity [17], protein deposition, fibrin
aggregation, platelet or other cellular phenomena triggered
by the test strip [10]. Interestingly, capillary samples were
identified as a factor in the difference between LAB PCx and
PG values but not between RN PCx and PG values. This
may be due to greater hemolysis occurring post RN PCx
analysis for a capillary specimen compared to a venous or
arterial sample. Accelerated aggregation of red blood cells
may result in more plasma water passing through the filter
membrane. Aggregation of red blood cells can be triggered
by free radicals and antioxidants through activated poly-
morphoneutrophils [18]. One study demonstrated
increased oxidants to antioxidant ratios in infants within
the first 72 hours of birth [19]. The neonatal red blood cell
is also structurally different from adult red blood cells [20].
Neonatal red blood cells have a larger cell volume and
hemoglobin concentration than do adult red blood cells.
They are also more fragile [21] and thus may be broken
more readily when applied to the barbed-like mesh of a fil-
ter membrane. Furthermore, drugs and altered pH can
affect the measurement of glucose using strip-based glucose
meters [10]. One or more of these unmeasured variables
may have contributed to the observed difference between
the glucose meter values and the laboratory values.
Conclusion
Our results show that screening for neonatal hypoglycemia
using the PCx glucose meter provides an estimate of blood
glucose but it also requires confirmation with the more
accurate and precise laboratory analyzer. The optimal
screening cut off for confirmatory testing is dependent on
what is an acceptable PPV. Hematocrit and low glucose
concentration are the most significant variables contribut-
ing to the difference between bedside glucose meter and
laboratory analyzer measurements.
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